| dc.contributor.author |
Jindal, Anil B. |
|
| dc.date.accessioned |
2025-02-27T05:04:14Z |
|
| dc.date.available |
2025-02-27T05:04:14Z |
|
| dc.date.issued |
2024-08 |
|
| dc.identifier.uri |
https://www.sciencedirect.com/science/article/pii/S135964462400196X |
|
| dc.identifier.uri |
http://dspace.bits-pilani.ac.in:8080/jspui/handle/123456789/18053 |
|
| dc.description.abstract |
Rheumatoid arthritis (RA) is an immune-mediated disease that necessitates a thorough understanding of its intricate pathophysiological mechanism for precise and effective therapeutic targeting. The European League Against Rheumatism (EULAR) has established guidelines for RA treatment, endorsing monotherapy or combination therapy with corticosteroids and synthetic disease-modifying antirheumatic drugs (sDMARDs). This review delves into clinical trials and research outcomes related to combination drug delivery, with an emphasis on the role of natural products in combination with synthetic drugs. Given the significant adverse effects associated with systemic administration, topical delivery has emerged as an alternative avenue for effective management of RA. |
en_US |
| dc.language.iso |
en |
en_US |
| dc.publisher |
Elsevier |
en_US |
| dc.subject |
Mechanical Engineering |
en_US |
| dc.subject |
Rheumatoid arthritis |
en_US |
| dc.subject |
Combination delivery |
en_US |
| dc.subject |
DMARDs |
en_US |
| dc.subject |
Natural products |
en_US |
| dc.title |
Recent innovations in topical delivery for management of rheumatoid arthritis: a focus on combination drug delivery |
en_US |
| dc.type |
Article |
en_US |